Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
50%(5 trials)

Phase Distribution

Ph not_applicable
2
15%
Ph phase_2
5
38%
Ph phase_4
1
8%
Ph phase_1
4
31%
Ph phase_3
1
8%

Phase Distribution

4

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
1(7.7%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(10)
Terminated(1)
Other(2)

Detailed Status

Completed10
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (30.8%)
Phase 25 (38.5%)
Phase 31 (7.7%)
Phase 41 (7.7%)
N/A2 (15.4%)

Trials by Status

withdrawn18%
unknown215%
completed1077%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_1

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

NCT01959633
completedphase_2

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

NCT00665353
completedphase_3

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

NCT00732641
completedphase_2

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00978497
completednot_applicable

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

NCT00249574
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01959633Phase 1

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation

Completed
NCT00665353Phase 2

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

Completed
NCT00732641Phase 3

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

Completed
NCT00978497Phase 2

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Completed
NCT00249574Not Applicable

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

Completed
NCT00759200Phase 2

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Completed
NCT01528735Phase 2

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Completed
NCT01547312Phase 1

Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

Withdrawn
NCT01704521Phase 1

Viral Kinetics in HCV Clearance in Subjects With Hemophilia

Completed
NCT00735969Phase 2

High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

Completed
NCT01731301Phase 4

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

Unknown
NCT01083251Not Applicable

The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection

Unknown
NCT00251199Phase 1

VX-950 and Peginterferon for Hepatitis C

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13